Trust experience, choose confidence1,2,3


Bracco was proud to launch the first ready-to-use non-ionic contrast agent, Jopamiro®, in 1981. This agent helped consolidate Bracco, as a global leader in the X-Ray contrast media market and research. Since the launch of Jopamiro® in 1981 many other non-ionic compounds have been made available. However, Jopamiro® remains the non-ionic agent of choice for thousands of clinicians world-wide.

Jopamiro® is sold in more than 80 countries through affiliates, partners, distributors and licensees1. Its long history and unique physicochemical properties2 have gained Jopamiro® many unique distinctions, including:


  • The first ready-to-use non-ionic agent with the 370 mg/mL concentration1
  • The subject of over 2000 scientific publications 3;Administered in over 400 million doses1;
  • Approved in a wide range of indications (including paediatric), concentrations and volumes2;
  • A proven safety profile in at risk patients4,5.
  • The advent of MDCT and new CT applications (cardiac, vascular, perfusion, etc) required clinicians to adjust their contrast protocols in particular in terms of volume, concentration and administration rate. Many renowned experts strongly promote the use of high concentration non-ionic agents in an effort to best exploit contrast utilization6. The use of high concentration best matches the speed and power of multi-slice scanners, providing earlier, higher and shorter enhancement peak.
  • Furthermore, Jopamiro® has proven to be well tolerated in many study cohorts. In particular, in renally-impaired patients two large comparative studies show that the risk of CIN (Contrast Induced Nephropathy), when the highly concentrated Iopamiro-370 is used in CT or during catheter endovascular procedures even in a subset of patients with diabetes, is not statistically different from that of iodixanol-3204,5, which provides inferior enhancement in first pass MDCT7.
  • The efficacy of high iodine concentration and the positive results even in patients at risk of developing CIN make Jopamiro® particularly indicated also for intra-arterial use in angiography and cardiangiography procedures where the volume of contrast and the risk of renal complications are highest5.

Contact us

Please fill out the form below and we will get back to you.

Different countries may have specific processes in place to handle reports of adverse reactions. To report an adverse reaction related to Bracco products, you can find specific contacts and information selecting the page "Pharmacovigilance" of your country.

* I have read the BraccoHealthCare Professionals Privacy Notice and I consent to the processing of my personal data allowing Bracco Imaging SpA (Data Controller) to conduct its business or scientific operations and contact me with promotional communication through email, SMS, and other digital and offline channels, such as mobile apps and social media.



For any product or type of product, whether a drug or device, referenced in this website, physicians should carefully review the product's package insert, instructions for use, or user manual prior to patient administration to ensure proper utilization of the product. The Core Summaries of Product Characteristics for the main Bracco Imaging products are available on line. However, please consult your full locally approved information before using.